Wells Fargo’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $89 | Sell |
10
-250
| -96% | -$2.93K | ﹤0.01% | 6518 |
|
|
2025
Q4 | $3.87K | Buy |
260
+250
| +2,500% | +$4.36K | ﹤0.01% | 6150 |
|
|
2025
Q3 | $192 | Hold |
10
| – | – | ﹤0.01% | 6351 |
|
|
2025
Q2 | $111 | Sell |
10
-380
| -97% | -$3.34K | ﹤0.01% | 6470 |
|
|
2025
Q1 | $5.46K | Buy |
390
+380
| +3,800% | +$5.95K | ﹤0.01% | 6009 |
|
|
2024
Q4 | $166 | Hold |
10
| – | – | ﹤0.01% | 6380 |
|
|
2024
Q3 | $189 | Hold |
10
| – | – | ﹤0.01% | 6231 |
|
|
2024
Q2 | $145 | Sell |
10
-1,560
| -99% | -$26K | ﹤0.01% | 6218 |
|
|
2024
Q1 | $24.3K | Buy |
1,570
+170
| +12% | +$3.67K | ﹤0.01% | 5524 |
|
|
2023
Q4 | $39.2K | Sell |
1,400
-8,264
| -86% | -$217K | ﹤0.01% | 5364 |
|
|
2023
Q3 | $460K | Buy |
9,664
+1,074
| +13% | +$82K | ﹤0.01% | 3839 |
|
|
2023
Q2 | $823K | Buy |
8,590
+5,844
| +213% | +$636K | ﹤0.01% | 3602 |
|
|
2023
Q1 | $311K | Buy |
2,746
+2,683
| +4,259% | +$290K | ﹤0.01% | 4160 |
|
|
2022
Q4 | $7.07K | Sell |
63
-146
| -70% | -$19.6K | ﹤0.01% | 5679 |
|
|
2022
Q3 | $26K | Buy |
209
+45
| +27% | +$4.61K | ﹤0.01% | 5274 |
|
|
2022
Q2 | $12K | Sell |
164
-321
| -66% | -$27.7K | ﹤0.01% | 5671 |
|
|
2022
Q1 | $70K | Sell |
485
-1,167
| -71% | -$180K | ﹤0.01% | 5494 |
|
|
2021
Q4 | $275K | Sell |
1,652
-1,106
| -40% | -$176K | ﹤0.01% | 5082 |
|
|
2021
Q3 | $384K | Buy |
2,758
+1,305
| +90% | +$255K | ﹤0.01% | 4811 |
|
|
2021
Q2 | $693K | Sell |
1,453
-1,584
| -52% | -$668K | ﹤0.01% | 4445 |
|
|
2021
Q1 | $1.25M | Sell |
3,037
-2,891
| -49% | -$1.33M | ﹤0.01% | 4087 |
|
|
2020
Q4 | $2.9M | Sell |
5,928
-851
| -13% | -$498K | ﹤0.01% | 3216 |
|
|
2020
Q3 | $3.84M | Buy |
6,779
+1,965
| +41% | +$653K | ﹤0.01% | 2751 |
|
|
2020
Q2 | $459K | Buy |
4,814
+722
| +18% | +$63.3K | ﹤0.01% | 4391 |
|
|
2020
Q1 | $292K | Buy |
4,092
+441
| +12% | +$29.6K | ﹤0.01% | 4433 |
|
|
2019
Q4 | $252K | Buy |
3,651
+334
| +10% | +$24.8K | ﹤0.01% | 4820 |
|
|
2019
Q3 | $266K | Buy |
3,317
+1,344
| +68% | +$88.8K | ﹤0.01% | 4785 |
|
|
2019
Q2 | $127K | Buy |
1,973
+957
| +94% | +$90.8K | ﹤0.01% | 5197 |
|
|
2019
Q1 | $139K | Buy |
1,016
+505
| +99% | +$61.6K | ﹤0.01% | 5002 |
|
|
2018
Q4 | $46K | Sell |
511
-10
| -2% | -$1.4K | ﹤0.01% | 5552 |
|
|
2018
Q3 | $79K | Buy |
521
+38
| +8% | +$6.15K | ﹤0.01% | 5445 |
|
|
2018
Q2 | $84K | Sell |
483
-1,008
| -68% | -$165K | ﹤0.01% | 5447 |
|
|
2018
Q1 | $219K | Buy |
1,491
+32
| +2% | +$6.14K | ﹤0.01% | 4941 |
|
|
2017
Q4 | $296K | Buy |
1,459
+755
| +107% | +$155K | ﹤0.01% | 4759 |
|
|
2017
Q3 | $226K | Sell |
704
-130
| -16% | -$35.5K | ﹤0.01% | 4864 |
|
|
2017
Q2 | $188K | Sell |
834
-692
| -45% | -$142K | ﹤0.01% | 4826 |
|
|
2017
Q1 | $344K | Sell |
1,526
-3,336
| -69% | -$677K | ﹤0.01% | 4492 |
|
|
2016
Q4 | $963K | Buy |
4,862
+4,555
| +1,484% | +$993K | ﹤0.01% | 3728 |
|
|
2016
Q3 | $75K | Sell |
307
-15
| -5% | -$5.26K | ﹤0.01% | 5082 |
|
|
2016
Q2 | $187K | Buy |
322
+80
| +33% | +$46.9K | ﹤0.01% | 4448 |
|
|
2016
Q1 | $129K | Buy |
242
+24
| +11% | +$12.5K | ﹤0.01% | 4670 |
|
|
2015
Q4 | $153K | Buy |
218
+216
| +10,800% | +$142K | ﹤0.01% | 4628 |
|
|
2015
Q3 | $1K | Buy |
+2
| New | +$1.63K | ﹤0.01% | 6064 |
|
Other funds holding MCRB
FP
VCM
VFT
Wells Fargo's MCRB Position: Q1 2026 in Review
Wells Fargo reduced its Seres Therapeutics (MCRB) stake by 96% in Q1 2026, selling an estimated $2.93K and leaving 10 shares worth $89. The position accounts for ﹤0.01% of the portfolio, ranked #6518.
Wells Fargo first reported a position in MCRB in Q3 2015 and has held it in 43 quarters since. The position peaked at $3.84M in Q3 2020. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.
- Wells Fargo held 10 shares of Seres Therapeutics worth $89 as of Q1 2026.
- Wells Fargo sold 250 Seres Therapeutics shares in Q1 2026, an estimated $2.93K.
- Seres Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6518 holding.
- Wells Fargo first reported a position in Seres Therapeutics in Q3 2015 and has held it in 43 quarters since.
- Wells Fargo's Seres Therapeutics position peaked at $3.84M in Q3 2020.
- 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.